These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Insurers and oncologists forge a better cancer drug policy. Butcher L Manag Care; 2008 Apr; 17(4):28-30. PubMed ID: 18464570 [No Abstract] [Full Text] [Related]
3. When reimbursement issues go beyond reimbursement. Abraham BC J Oncol Manag; 2002; 11(6):31-2. PubMed ID: 12502291 [No Abstract] [Full Text] [Related]
4. A conversation with Lee N. Newcomer, MD, MHA. Payments with purpose. Interview by John Marcille. Newcomer LN Manag Care; 2011 Dec; 20(12):36-40. PubMed ID: 22259875 [No Abstract] [Full Text] [Related]
5. Navigating the business of oncology for 2008. Crisafulli T Semin Oncol; 2008 Feb; 35(1):1-5. PubMed ID: 18308138 [No Abstract] [Full Text] [Related]
6. The professional component of chemotherapy administration--what is the issue? Bailes JS Oncology (Williston Park); 1991 Aug; 5(8):16. PubMed ID: 1834150 [No Abstract] [Full Text] [Related]
7. Oncology reimbursement overview: drug purchasing arrangements and profitability. Crisafulli T Semin Oncol; 2008 Aug; 35(4):321-3. PubMed ID: 18692681 [No Abstract] [Full Text] [Related]
8. The Oncology Care Model-Why It Works and Why It Could Work Better: Accounting for Novel Therapies in Value-Based Payment. Lyss AJ; Supalla SN; Schleicher SM JAMA Oncol; 2020 Aug; 6(8):1161-1162. PubMed ID: 31670756 [No Abstract] [Full Text] [Related]
9. Oncology reimbursement in the era of personalized medicine and big data. Ward JC J Oncol Pract; 2014 Mar; 10(2):83-6. PubMed ID: 24633283 [No Abstract] [Full Text] [Related]
10. Reimbursement for medical care in the USA. Simone JV Lancet Oncol; 2009 Mar; 10(3):198-9. PubMed ID: 19261247 [No Abstract] [Full Text] [Related]
12. Oncology Pathways-Preventing a Good Idea From Going Bad. Polite BN; Page RD; Nabhan C JAMA Oncol; 2016 Mar; 2(3):297-8. PubMed ID: 26847876 [No Abstract] [Full Text] [Related]
13. [Report of the Treasurer, Society of Hungarian Oncologists, November 2005 to November 2007)]. Vincze B Magy Onkol; 2008 Mar; 52(1):99-101. PubMed ID: 18403305 [No Abstract] [Full Text] [Related]
14. MACRA in Oncology Care: Are We Ready? Nabhan C; Tchafa A; Feinberg BA J Oncol Pract; 2017 Dec; 13(12):777-779. PubMed ID: 29144865 [No Abstract] [Full Text] [Related]
15. Are centers and practices implementing changes to their reimbursement or payment models? An NCCN Trends report. Guinto JB J Natl Compr Canc Netw; 2013 Jul; 11(7):904-5. PubMed ID: 23847223 [No Abstract] [Full Text] [Related]
17. StatBite: Survey: Oncologists on Costs and Treatment. J Natl Cancer Inst; 2009 Nov; 101(21):1443. PubMed ID: 19828872 [No Abstract] [Full Text] [Related]
18. The economics of reimbursement and technological change in cancer care. Kesteloot K Eur J Cancer; 1995; 31A(9):1406-9. PubMed ID: 7577063 [No Abstract] [Full Text] [Related]
19. [Report of the General Secretary, Society of Hungarian Oncologists, November 2005 to November 2007)]. Landherr L Magy Onkol; 2008 Mar; 52(1):97-8. PubMed ID: 18403304 [No Abstract] [Full Text] [Related]
20. Pricing and reimbursement of pharmaceuticals in the Baltic States. Freemantle N; Behmane D; de Joncheere K Lancet; 2001 Jul; 358(9278):260. PubMed ID: 11498210 [No Abstract] [Full Text] [Related] [Next] [New Search]